FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Response	s)										
1. Name and Address o SAENGER BRADI	2. Issuer Name <b>an</b> Tonix Pharmaceu			0.2		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) C/O TONIX PHAR CORP, 509 MADIS	S HOLDING	3. Date of Earliest Transaction (Month/Day/Year) 05/27/2016						X_Officer (give title below)         Other (specify below)           Chief Financial Officer			
NEW YORK, NY 1		4. If Amendment, D	ate Origina	l File	d(Month/Da	y/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	c) (Zip) Table I - Non-Derivative Securities A						Acqu	ired, Disposed of, or Beneficially Ov	vned	
1.Title of Security		2. Transaction	2A. Deemed 3. Transaction 4. Securities Acquired						5. Amount of Securities Beneficially	6.	7. Nature
(Instr. 3)		Date							Owned Following Reported	Ownership	of Indirect
	any	(Instr. 8) (Instr. 3, 4 and			4 and 5)		Transaction(s)	Form:	Beneficial		
			(Month/Day/Year)				(Instr. 3 and 4)	Direct (D)	Ownership		
									or Indirect	(Instr. 4)	
							(A) or			(I)	
				Code	V	Amount	(D)	Price		(Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number 6. I		6. Date Exercisable and		7. Title and		8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	ion	n of E		Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivativ	Derivative (Month/Day/Year)		Underlying Security		Security	Securities	Form of	Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securitie	es			Securities		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquired	h			(Instr. 3 and 4)					(Instr. 4)
	Security					(A) or							0	Direct (D)	
						Disposed	d of					1	or Indirect		
						(D) (In star 2	4					Transaction(s)	· /		
						(Instr. 3, and 5)	4,					(Instr. 4)	(Instr. 4)		
						and 5)			r						
											Amount				
								Date	Expiration	Title	or Number				
								Exercisable	Date	Titte	of				
				Code	v	(A)	(D)				Shares				
Stock						( -)	(-)			Common					
	\$ 2.42	05/27/2016		А		20,000		<u>(1)</u>	05/27/2026	Common Stock	20,000	\$ 0 <u>(2)</u>	20,000	D	
Option										STOCK					
Stock	\$ 2.42	05/27/2016		А		60,000		<u>(3)</u>	05/27/2026	Common Stock	60.000	\$ 0 <u>(2)</u>	60.000	D	
Option	φ 2.42	03/2//2010		A		00,000		<u></u>	05/2//2020	Stock	00,000	\$ 0 <u>127</u>	00,000	D	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
Reporting Owner Manie / Address	Director	10% Owner	Officer	Other			
SAENGER BRADLEY C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022			Chief Financial Officer				

## Signatures

/s/ Jessica Morris, Attorney-in-Fact	05/31/2016
**Signature of Reporting Person	Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.

(2) The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan.

(3) The option vests 1/3rd upon the date(s) that certain stock price goals are achieved. The stock price goals are such date(s) when the Issuer's common stock has an average closing sales price equal to or exceeding each of \$6.00, \$7.00 and \$8.00 per share for 20 consecutive trading days, subject to a one year minimum service period prior to vesting.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.